EyePoint to Cut Workforce 53% After Experimental Drug Fails Trial
EyePoint said it would cut about 53% of its workforce and stop studies of its experimental drug for an age-related vision disease after the drug failed a second late-stage trial.
EyePoint NASDAQ:EYPT on Monday said it would cut about 53% of its workforce and stop studies of its experimental eye drug for an age-related vision disease after it failed a second late-stage trial.Here are more details